Type2 Diabetes
Conditions
Brief summary
The study will assess the glycemic variationusing continuous glucose monitoring system in type 2 diabetic patients with euglycemia control respectively when patients was treated with Basalin and one week after changing the insulin into Lantus.
Detailed description
The participants will take continuous glucose monitoring system for 3 days when they change the insulin into Lantus after reach euglycemia control with Basalin treatment for one week.
Interventions
DRUGBasalin to Lantus
continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
Sponsors
Nanjing First Hospital, Nanjing Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Patients with T2DM, which was defined bypublished Criteria of World Health Organization in 1999; 2. Patients were using Basalin with or without oral hypoglycemic drugs and having a stable dose of glargine for more than 3 month would be recruited into this study; 3. Patients had relatively constant diet and exercise in 2 month before the study. 4. Fasting blood glucose\<6.1mmol/L, and postprandial (or random) blood glucose \<14mmol/L
Exclusion criteria
1. Patients with severe cardiovascular diseases, such as stroke, transient ischemic attack, myocardial infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary intervention, and heart failure; 2. Patients with severe infectious diseases; 3. Patients with acute complications of diabetes on admission, such as diabetic ketoacidosis, diabetic hyperosmolar nonketotic coma, and lactic acidosis; 4. Patients with history of psychiatric disorders and were unsuitable to use CGMS; 5. Any other situations that made patients unsuitable to participate in the study, such as alcoholism and drug abuse.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of glycemic variation | Day 1-13 | The changes of glycemic variation before and after drug change |
Countries
China
Contacts
Primary ContactMa Jianhua
Outcome results
None listed